Announcements
- Supernus to Participate in Two Upcoming Investor Conferences
- Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
- Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
- Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
- Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
- Supernus Announces Third Quarter 2023 Financial Results
- Supernus to Participate in the Jefferies London Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
- Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
- Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
More ▼
Key statistics
On Thursday, Supernus Pharmaceuticals Inc (S49:FRA) closed at 31.00, -11.43% below its 52-week high of 35.00, set on Apr 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.00 |
---|---|
High | 31.00 |
Low | 31.00 |
Bid | -- |
Offer | -- |
Previous close | 29.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 54.73m |
Free float | 51.93m |
P/E (TTM) | 1,330.97 |
Market cap | 1.85bn USD |
EPS (TTM) | -0.0152 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:00 BST.
More ▼